A Clinical Stage Company

Developing small molecules targeting cancers, metabolic, neurodegenerative
and autoimmune diseases.

See Pipeline

Our unique AI-enabled process designs innovative NCEs targeting any class of protein at unprecedented speed.

MOLECULERN PROCESS

Identify and validate structural proteins
Characterize target druggability through In Silico MolecuLern-driven workflow and experimental data

Real data tracking models
Hotspot residues

Validate binding pocket
AA property ennumeration

Iterative screening
Med-Chem tractability
Lead identification/selection

NCEs to synthesis
SAR to complete lead selection

ADME-Tox
Developability
Pre-formulation

Efficacy
Scale-up

MolecuLern Process PDF

Precise

Your training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions and discover targetable hot spots which minimizes the hit-and-miss nature of traditional drug discovery.

Accelerated

Cutting-edge platform based on decades of work, supported by over 5 years of AI/ML development that discovers new medicines with previously impossible speed and accuracy.

Validated

MolecuLern has been trained on hundreds of 3D structures, from both PDB and DeepMind AlphaFold protein targets, screened against our IP rich proprietary fragment and NCE library.